177Lu-DTPA-Omburtamab

177Lu-DTPA-omburtamab · Y-mAbs Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 177Lu-DTPA-Omburtamab, covering 2023-10-06 to 2023-10-06. Get the full timeline:

Most recent: Clinical Trial Update: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma [Phase 1, Phase 2]